Autologous Epstein-Barr virus-specific T-cell therapy - bluebird bio/University College London

Drug Profile

Autologous Epstein-Barr virus-specific T-cell therapy - bluebird bio/University College London

Alternative Names: Autologous EBV-CTL - bluebird; Autologous Epstein-Barr virus-specific T-cell therapy - bluebird bio/University College London; EBV-CTL - bluebird/University College London; EBV-specific T-cells - bluebird bio/University College London; Epstein-Barr virus specific cytotoxic T-lymphocytes - bluebird bio/University College London; Tacrolimus resistant EBV-CTL -bluebird; Tacrolimus-resistant autologous Epstein-Barr virus-specific T-cell therapy - bluebird

Latest Information Update: 04 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator bluebird bio; University College London
  • Class Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Post-transplant lymphoproliferative disorder

Most Recent Events

  • 24 Apr 2017 Preclinical trials in Post-transplant lymphoproliferative disorder in United Kingdom prior to April 2017 (IV)
  • 24 Apr 2017 bluebird bio in collaboration with University College London plans a phase I trial for Post-transplant lymphoproliferative disorder (In infants; In children; In adolescents; In adults; In the elderly) in United Kingdom (NCT03131934)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top